AKT1 and cystic fibrosis: Inhibitors of the PI3K/Akt/mTOR pathway are therapeutic targets in misfolding disease39 and the Akt inhibitor 10-DEBC has been previously shown improve ΔF508 CFTR stability in CF cells40.